HilleVax Announces Appointment of Nanette Cocero Ph.D., MBA, to its Board of Directors
09 Mai 2023 - 1:00PM
HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical
company focused on developing and commercializing novel vaccines,
today announced the appointment of Nanette Cocero, Ph.D., MBA, to
its Board of Directors, effective May 8, 2023. Dr. Cocero served as
the Global President of Pfizer Vaccines during the last four years
and is a recognized leader in global healthcare.
“I am pleased to welcome Nanette, a highly respected and
experienced leader in vaccines, as an independent director to the
HilleVax board” said Rob Hershberg, MD, PhD, Chairman and Chief
Executive Officer of HilleVax. “Nanette brings extensive experience
in development and delivery of innovative vaccines to drive the
prevention of serious and life-threatening conditions. We look
forward to her meaningful impact and many contributions to the
board.”
Dr. Cocero is a seasoned pharmaceutical executive with over 25
years of experience in diverse leadership positions. Most recently,
Dr. Cocero was the Global President of Pfizer Vaccines where she
led an over $30B global business and managed a diverse vaccines
portfolio aimed at protecting lives at all stages, from infants to
older adults. Dr. Cocero was responsible for the development,
global commercialization, and delivery of >2B doses of the
Pfizer-BioNTech COVID-19 Vaccine to 152 countries and territories
around the world. Throughout her 21-year tenure at Pfizer, she held
a number of senior positions touching every market of the world,
from United States, Europe and Japan to emerging
markets. Before joining Pfizer, Nanette was a
management consultant in the biotech and pharmaceutical industries.
Nanette earned a Bachelor of Science degree in chemistry from
Cornell University, a Ph.D. in pharmacology from the University of
Pennsylvania, and an MBA from The Wharton Business School.
About HilleVax
HilleVax is a clinical-stage biopharmaceutical company focused
on developing and commercializing novel vaccines. Its initial
program, HIL-214, is a virus-like particle (VLP) based vaccine
candidate in development for the prevention of moderate-to-severe
acute gastroenteritis (AGE) caused by norovirus infection.
Globally, norovirus is estimated to result in over approximately
700 million cases of AGE and 200,000 deaths per year, resulting in
over $4 billion in direct health system costs and $60 billion in
societal costs per year. The burden of norovirus falls
disproportionately on young children and older adults. For more
information about HilleVax, visit the company’s website at
http://www.HilleVax.com.
Contact:Shane
MaltbieIR@hillevax.com+1-617-213-5054
HilleVax (NASDAQ:HLVX)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
HilleVax (NASDAQ:HLVX)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024